NICE Draft Guidance Suggests Sponge Tests for Barrett’s and Cancer
Thousands of people with persistent indigestion could soon be offered a seven-minute capsule test on the NHS to check for cell changes in the food pipe, draft guidance from the National Institute for Health and Care Excellence shows.
- The capsule sponge test checks for Barrett’s oesophagus and early cancer signs in patients with long-term acid reflux.
- The non-sedative procedure can be performed in GP surgeries, local pharmacies, and community diagnostic centers.
- Final recommendations from the National Institute for Health and Care Excellence are expected in the new year.
Between one and two adults in every 100 have Barrett’s oesophagus, a condition where stomach acid damages the lining of the gullet and causes cells to change, according to NICE. While most patients do not go on to develop cancer, high demand for endoscopies means some individuals are not checked as frequently as recommended.
The diagnostic process involves swallowing a small dissolving capsule attached to a thread, which releases a tiny sponge once it reaches the stomach.
“Capsule sponge tests offer a quick and less invasive way to detect concerning changes associated with oesophageal cancer or Barrett’s oesophagus, helping to identify people who should go on to have further tests and treatment.”
Jonathan Benger, chief executive of NICE
The sponge collects cell samples from the oesophageal lining for laboratory analysis. The procedure can be administered in local pharmacies, GP surgeries, and community diagnostic centers without the need for sedation.

Thousands of patients have already benefited from pilot schemes running across England. The National Institute for Health and Care Excellence has recommended two specific tests, Cytosponge and EndoSign, for deployment under the new draft guidance.
“The NHS is always looking for better ways to get to the bottom of people’s symptoms, and thousands have already benefited from this incredibly efficient test through pilots we have been running, so it’s fantastic it is now being considered for roll out across the country.”
Peter Johnson, national clinical director for cancer at NHS England
More than 9,000 people are diagnosed with oesophageal cancer each year in the UK. Because the disease is often detected late when treatment is difficult, expanding access to easier diagnostics aims to help the NHS free up endoscopy capacity and find cancers earlier.
The tests also offer a way for patients with reflux disease to monitor their condition over time. However, health officials note that no diagnostic test identifies every single case of disease.
Patients who receive an all-clear sponge test result still require long-term monitoring, according to the National Institute for Health and Care Excellence. Final recommendations on the national rollout will be made in the new year.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.
Worth a look